Your AI-Trained Oncology Knowledge Connection!
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.
Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.
The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.
Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.
Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.
Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.
Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.
The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.
Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.
The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.
The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.
Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.
The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.
Patients with cancer who have venous thromboembolism had similar rates of recurrent VTE or bleeding with the oral factor Xa inhibitor edoxaban (Savaysa) or the low-molecular weight heparin dalteparin (Fragmin).
Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.
Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.
Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.
The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).
Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.
Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma.
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL.
Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.
A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.
Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.
Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.
